Cristina Birzu
University of Paris
GeneCell cycle checkpointOphthalmologyMutation (genetic algorithm)CancerInternal medicinePhenotypeSomatic hypermutationOncologyAKT1Precision medicineTelomereChemistryDNA methylationAdverse effectCTLA-4T cellRegorafenibPBRM1PolyradiculoneuropathyTemozolomideImmunotherapyStandard treatmentOligodendrogliomaMyasthenia gravisGliomaOptic neuropathyDiscontinuationThymomaMeningiomaTumor progressionO-6-methylguanine-DNA methyltransferaseMicrosatellite instabilityNivolumabPembrolizumabCDKN2ATargeted therapyMyositisGlioneuronal tumorGene mutationRadiation inducedBAP1Cancer researchClinical trialCarcinogenesisBioinformaticsDNA mismatch repairClinical significanceMedicineBiologyTelomerase
11Publications
3H-index
129Citations
Publications 11
Newest
#1Julie Boyer (University of Paris)
#2Cristina Birzu (University of Paris)H-Index: 3
Last. Ahmed Idbaih (University of Paris)H-Index: 64
view all 7 authors...
Source
#1Cristina Birzu (University of Paris)H-Index: 3
Last. Florence Laigle-DonadeyH-Index: 31
view all 7 authors...
Introduction Les tumeurs glioneuronales leptomeningees primitives diffuses (TGNLD) sont des tumeurs rares de l’enfant. Les cas adultes sont exceptionnels. Objectifs Notre objectif est d’ameliorer la connaissance des TGNLD chez l’adulte, en decrivant leurs caracteristiques cliniques et paracliniques, en les comparant aux donnees connues de la litterature dans la population pediatrique. Patients et methodes Nous avons identifie de facon retrospective les patients adultes suivis dans notre service ...
Source
#1Cristina Birzu (University of Paris)H-Index: 3
#2Michel Kalamarides (University of Paris)H-Index: 30
Last. Marc Sanson (University of Paris)H-Index: 30
view all 7 authors...
Introduction Les meningiomes associes aux progestatifs (MAP) sont insuffisamment explores malgre une incidence recemment augmentee. Il n’existe actuellement pas de connaissance sur le profil epigenetique ou d’elements predictifs de l’evolution radiologique. Objectifs L’objectif de cette etude est l’analyse radiologique et radiomique du profil evolutif des MAP a l’arret du traitement, et caracterisation du profil moleculaire et epigenetique des MAP. Patients et methodes A partir de la base de don...
Source
#1Cristina Birzu (University of Paris)H-Index: 3
#2Pim J. French (Erasmus University Medical Center)H-Index: 51
Last. Giuseppe LombardiH-Index: 26
view all 7 authors...
Glioblastoma is the most frequent and aggressive form among malignant central nervous system primary tumors in adults. Standard treatment for newly diagnosed glioblastoma consists in maximal safe resection, if feasible, followed by radiochemotherapy and adjuvant chemotherapy with temozolomide; despite this multimodal treatment, virtually all glioblastomas relapse. Once tumors progress after first-line therapy, treatment options are limited and management of recurrent glioblastoma remains challen...
3 CitationsSource
#1Cristina BirzuH-Index: 3
#1Cristina BirzuH-Index: 1
Last. Felix SahmH-Index: 58
view all 3 authors...
Purpose of review To discuss recent advances in the meningioma biology and their clinical implications. Recent findings Meningioma is the most common primary intracranial tumor. Mostly benign, 20% of cases display an aggressive behavior despite best standard of care. The genetic landscape of meningiomas is divided according to NF2 mutational status. Although about 60% of meningiomas display NF2 mutations, the other share is more heterogenous. Mutations in TRAF7, SMO, v-akt murine thymoma viral o...
1 CitationsSource
#1M.L. Raffin-SansonH-Index: 2
Last. Michel Kalamarides (University of Paris)H-Index: 30
view all 14 authors...
Contexte Les meningiomes sont des tumeurs intracrâniennes plus frequentes chez les femmes et favorisees par les grossesses. L’acetate de cyproterone, un progestatif synthetique aux effets anti androgeniques, a ete retrouve associe a une augmentation du risque de meningiome, proportionnellement a la dose cumulee. Cet effet est observe pour d’autres progestatifs (Acetate de chlormadinone, acetate de nomegestrol). Patients et methodes Nous avons repris les donnees cliniques, histologiques et molecu...
Source
#1Mehdi Touat (Broad Institute)H-Index: 18
#2Yvonne Y. Li (Broad Institute)H-Index: 25
Last. Keith L. LigonH-Index: 92
view all 78 authors...
A high tumour mutational burden (hypermutation) is observed in some gliomas1–5; however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here we comprehensively analyse the molecular determinants of mutational burden and signatures in 10,294 gliomas. We delineate two main pathways to hypermutation: a de novo pathway associated with constitutional defects in DNA polymerase and mismatch repair (MMR) genes, and a more commo...
79 CitationsSource
#1Dimitri Psimaras (University of Paris)H-Index: 29
#2Roser Velasco (Autonomous University of Barcelona)H-Index: 21
Last. Andreas A. ArgyriouH-Index: 37
view all 7 authors...
: Immune checkpoint inhibitors (ICIs) are increasingly used and are becoming the standard of care in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Neurological irAEs are rare but potentially severe. Neuromuscular disorders represent the most common neurological irAEs following anti-PD-1, anti-PD-L1, and anti-CTLA-4 treatment, and include myositis,...
14 CitationsSource
#1Mehdi Touat (Harvard University)H-Index: 18
#2Yi Li (Harvard University)H-Index: 94
Last. Keith L. Ligon (Harvard University)H-Index: 92
view all 30 authors...
1 CitationsSource
#1Cristina Birzu (University of Paris)H-Index: 3
#1C Birzu (University of Paris)
Last. Agusti Alentorn (University of Paris)H-Index: 17
view all 13 authors...
Source